Boas Práticas de Farmácia Hospitalar - Portal da Saúde

146
Referências Bibliográficas
1 Palella, F.J. Jr; Delaney KM, Moorman AC, e col. Declining morbidity and mortality among patients with
advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med.
1998; 338: 853-860.
2 Egger. M, May M, Chene G, e col. «Prognosis of HIV-1-infected patients starting highly active antiretroviral
therapy: a collaborative analysis of prospective studies.» Lancet. 2002; 360: 119-129.
3 Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors
for virologic failure and adverse drug reactions. Ann Intern Med. 1999; 131: 81-87.
4 Casado JL, Perez-Elias MJ, Antela A, e col. Predictors of long-term response to protease inhibitor
therapy in a cohort of HIV-infected patients. AIDS. 1998; 12: F131-135.
5 Piketty C, Race E, Castiel P, e col. «Efficacy of a five-drug combination including ritonavir, saquinavir and
efavirenze in patients who failed on a convetional triple-drug regimen: phenotypic resistance to protease
inhibitors predicts outcome of therapy.» AIDS. 1999; 13: F71-77.
6 Marzolini C, Telenti A, Decosterd LA, Grub G, iollaz J, Buclin T. «Efavirenz plasma levels can predict
treatment failure and central nervous system side effects in HIV-1-infected patients.» AIDS. 2001; 15:
71-75.
7 Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmaAdapt; a randomized prospective study to
evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS, 2002;
16: 2311-2315.
8 Malllas J, Blanco JL, Sarasa M, e col. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine
and lamivudine in HIV-infected patients. J Acquir Immune Defic Syndr. 200, 25: 229-235.
9 Casado JL, Moreno A, Sabido R, e col. A clinical study of the combination of 100 mg ritonavir plus
800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
HIV Clin Trials. 2000; 1: 13-19.
10 Seminari E, Maggiolo F, Villani P, e col. Efavirenze, nelfinavir, and stavudine rescue combination therapy
in HIV-1-positive patients heavlily pretreated with nucleoside analogues and protease inhibitors. J Acquir
Immune Defic Syndr. 1999; 22: 453-460.
11 Barry MG, Merry C, Lloyd J, e col. Variability in trough plasma saquinavir concentrations in HIV patients
– a case for therapeutic drug monitoring. Br J Clin Pharmacol. 1998; 45: 501--502.
12 Back D, Gatti G, Fletcher C, e col. Therapeutic drug monitoring in HIV infection: current status and
future directions. AIDS. 2002, 16 (suppl 1): S5-37.
13 Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II
evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996; 10: 485-492.
14 Burger DM, Hoetelmans RM, Hugen PW, e col. Low plasma concentrations of indinavir are related to
virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther.
1998, 3: 215-220.
15 Havlir D, Cheeseman SH, McLaughlin M, e col. High-dose nevirapine: safety, pharmacokinetics, and
antiviral effect in patients with immunodeficiency virus infection. J Infect Dis. 1995; 171: 537-545.
16 Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation
to indinavir plasma concentrations in HIV-1-infected patients. AIDS. 1999; 13: 473-478.